{
  "ticker": "NUZ",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02960356",
  "id": "02960356",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250620",
  "time": "0932",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250620/pdf/06ky1qwv7xyppq.pdf",
  "summary": "- **Rodent PK study confirms NUZ-001 and metabolite (NUZ-001 Sulfone) effectively cross blood-brain barrier (BBB) at therapeutically relevant CNS concentrations** (285\u20131,300 nM for NUZ-001; 177\u20131,231 nM for NUZ-001 Sulfone).  \n- **Repeat TDP-43 aggregation assay shows both compounds significantly prevent TDP-43 aggregation** in ALS patient-derived neurons at all tested concentrations (270\u20134,400 nM).  \n- **CNS concentrations overlap with levels proven to reverse TDP-43 pathology**, validating potential as disease-modifying therapy for ALS and other TDP-43 proteinopathies (e.g., FTD, Alzheimer\u2019s).  \n\n*No capital markets or liquidity-impacting information identified.*",
  "usage": {
    "prompt_tokens": 2039,
    "completion_tokens": 163,
    "total_tokens": 2202,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-20T00:00:05.926079"
}